About Michael Aiello
Michael Aiello is a chief financial officer at Invea Therapeutics.
Michael Aiello reports to the SEC as a major shareholder of 1 public company: BioXcel Therapeutics (BTAI).
Michael Aiello first appears on SEC filings in 2022.
Experience
This experience comes from SEC filings. The years are when the filings name Michael Aiello in the role, so the role may have started earlier or lasted longer.
BI
BioXcel Therapeutics, Inc.
10% owner
2023 · Public company (BTAI)
Key Colleagues at Startups
The people Michael Aiello works with at each company, as listed on that company's latest Form D.
Invea Therapeutics, Inc · Form D, Dec 10, 2025
DK
Demetrios Kydonieus
Director
AK
Aman Kant
President
SA
Salvatore Alesci
Chief Scientific Officer
JZ
Jonathan Zalevsky
Director
SO
Shunichiro "Steve" Okada
Chief Medical Officer
SD
Stephen Doberstein
Director
KB
Kerrie Brady
Director
KN
Krishnan Nandabalan
Chief Executive Officer and Chairman